Ingabe I-Liposomal NMN Ibiza Kakhulu Ngempela? Ukuhlukaniswa Kwezindleko Zangempela ze-BOM

Okwabaphathi bokuthengwa kwempahla nabanikazi bomkhiqizo abahlolayoliposomal NMN powder, umbuzo wokuqala uvame ukufana: ingabe izindleko eziphezulu zangaphambili ngekhilogremu zikhulisa ngokuzenzakalelayo izindleko zomkhiqizo oqediwe? Emaqenjini afunayo afaka izinqumo mayelana nenani lempahla eluhlaza, impendulo ivamise ukuncika ku-NMN evamile eshibhile. Kulabo abamodela Ingqikithi Yezinto Zokusebenza (i-BOM) okuhlanganisa ukusebenza kahle kwemithamo, isivuno sokukhiqiza, kanye nokuma komkhiqizo, i-liposomal NMN ivamise ukunikezela ngezindleko eziqhathanisekayo noma eziphansi ngomthamo ngamunye osebenzayo.

While NMN raw material prices have declined steadily-with high‑purity (>99%) impushana ye-NMN evamile manje ecashunwe ebangeni elingu-$90–$220 ngekhilogremu ngayinye{3}}inani leyunithi liyisendlalelo sokuqala kuphela sesibalo sokuthola usizo. Ngezansi ukuhlukaniswa komugqa ngomugqa ohlanganisa izindleko zezinto ezingavuthiwe, ukucutshungulwa kwe-encapsulation, ukulahlekelwa kokuwohloka, kanye nesici esinganakwa kakhulu sokutholakala kwe-bioavailability okusebenzayo.

 

 

Iphutha elivame kakhulu lokuthengwa kwempahla liwukuqhathanisa amanani ngekhilogremu ngaphandle kokulungisa amazinga okufakwa ahluke kakhulu adingekayo ukuze kuzuzwe imiphumela eqhathaniswayo yezinto eziphilayo. I-bioavailability yomlomo ye-NMN evamile ibhekene nezithiyo ezibhalwe kahle: ukuguqulwa kwe-enzymatic yamathumbu ku-nicotinamide, i-metabolism ye-hepatic esheshayo yokuqala, kanye nokuhluka okukhulu phakathi kwabantu. Ucwaningo lwango-2023 olwenziwe ngu-Yamane et al. ibonise ukuthi ngenkathi i-NMN yomlomo (i-250 mg nsuku zonke amaviki e-12) iphakamisa amazinga e-plasma NAD⁺, ubukhulu bokuphakama buhluka kakhulu phakathi kwabahlanganyeli, okugqamisa ukutholakala kwe-bioavailability okungahambisani kwe-NMN yomlomo engashintshiwe.

Isilingo sangaphambilini somtholampilo esihlola i-MIB‑626 (i-microcrystalline formulation ye-NMN) ibike ukuthi kanye-noma kabili-ngosuku izinhlobo ze-1,000 mg zikhiqize ukukhuphuka okuhlobene nomthamo kumazinga e-NAD⁺ egazi. Umthamo ophezulu ubonisa igebe lokusebenza kahle okufanele abenzi bamafomula balivale nge-NMN evamile. Ngokuphambene, i-liposomal encapsulation iklanyelwe ukuvikela i-NMN ku-asidi yesisu kanye nokuwohloka kwamathumbu, kube lula ukutholwa kwamaselula okuqondile kanye nokudlula i-first-pass metabolism yesibindi.

 

Ukuqhathaniswa komthamo:

Imethrikhi	I-NMN evamile	I-Liposomal NMN Powder
Izindleko zezinto ezingavuthiwe	Phansi ($90–220/kg)	Phezulu (2–3×)
Isilinganiso esisebenzayo esijwayelekile	500–1,000 mg/ngosuku (imvamisa ephakeme ngokuphakama kwe-NAD⁺)	250-500 mg / ngosuku
Ukuphakama kwe-NAD⁺	Okulingene (kungahluka phakathi kwabantu)	Okuphezulu nge-mg
Izindleko nge-mg esebenzayo ngayinye	Phezulu	Okuphansi noma ukuqhathanisa

Kubathengi be-B2B, lokhu kuguquguquka kokusetshenziswa komthamo kusho ukuthi umkhiqizo oqediwe oqondise umphumela ofanayo wokusebenza ungasebenzisa isithako esisebenza kancane kakhulu, unciphise noma ukhiphe igebe lezindleko zempahla eluhlaza.

 

 

Isinqumo sokuthenga esisekelwe kuphela enanini lezinto ezingavuthiwe sikhuthaza amabhrendi ukuthi asebenzise umthamo ovamile we-NMN womthamo ophezulu, okhuphula usayizi we-capsule, umthwalo we-excipient, kanye nemikhawulo yokukhiqiza. Indlela eyinkimbinkimbi yokuthenga iwukubalaizindleko ngempumelelo ngayinyei-milligram yokulethwa kwesistimu:

• Izindleko nge-mg esebenzayo ngayinye=(Impahla eluhlaza $/kg × Izinga lokufakwa) / Isici se-Bioavailability
• I-NMN evamile ingena ku-portal circulation futhi i-metabolized kakhulu yisibindi ngaphambi kokufinyelela izicubu ezihlosiwe.
• I-Liposomal NMN yeqa i-metabolism yokuqala ngohlelo lwe-lymphatic, iletha ingxenye enkulu yomthamo ongenisiwe ekujikelezeni kwesistimu.

Isibalo se-mg ye-cost‑per-effective-mg siphinde sibhekele izinqumo zomthamo oqhutshwa yi-biomarker. Ucwaningo lwe-rodent luqinisekisile ukuthi i-NMN yomlomo idlula i-first-pass metabolism emathunjini, ngokuguqulwa okuyingxenye ku-nicotinamide (NAM) ngaphambi kokungena ku-systemic circulation. Ucwaningo lwabantu oluphenya nge-NMN pharmacokinetics lubike ukuthi ngenkathi i-NMN yomlomo ikhiqiza ukwanda okulinganiselwe ku-plasma NAD⁺, ukuhlukahluka kokuphendula komuntu ngamunye kwakubalulekile, okuqinisa isidingo sezinhlelo zokulethwa ezithuthukisa ukubikezelwa.

 

 

Ukufaka i-encapsulation nokomisa{0}}noma ngabe ukomisa ngokufutha noma ukumisa iqhwa{1}}kwethula izindleko zokucubungula kanye nokulahlekelwa kwesivuno okungaba khona. Amadokhumenti athile eqoqo okusebenza kahle kwe-encapsulation, ukufana kosayizi wezinhlayiyana (imvamisa engu-100–300 nm), kanye nomswakama oyinsalela kuvumela amaqembu okuthenga ukuthi aqhathanise abahlinzeki ngamamethrikhi anengqondo kunentengo yodwa.

Izindleko ze-BOM ezifihliwe ekucubunguleni okujwayelekile kwe-NMN:

• Ukufakwa okuphezulu kwesithako esisebenzayo ukunxephezela ukutholakala okuncane kwe-bioavailability → usayizi wekhephuseli omkhulu, izindleko ze-excipient eziphezulu.
• Amandla okuhlukahluka kweqoqo-kuya-inqwaba emiphumeleni yokumuncwa → izikhalazo zabathengi nezindleko zokubuyisela.
• Ukuchayeka kakhudlwana ekonakaleni ngesikhathi somswakama ophezulu noma isitoreji sezinga lokushisa eliphakeme.

I-Liposomal NMN, ne-matrix yayo ye-phospholipid evikelayo, ngokuvamile inikeza impilo yeshelufu enwetshiwe yezinyanga eziyi-12-24 ngaphansi kwesitoreji esilawulwayo (epholile, esomile, esingangeni moya). Le ngozi encishisiwe yokuwohloka yehlisa izindleko eziphelele zobunikazi bemikhiqizo esabalalisa ezimakethe zomhlaba.

 

 

Ukwakheka kwezwe kokulawula kwe-NMN kuguquke kakhulu. Ngo-September 2025, ukuhunyushwa kwemithetho ezungeze i-NMN kuye kwavela, nezingxoxo eziqhubekayo mayelana nesimo sayo njengesithako sokudla e-United States. Nokho, i-NMN ihlukaniswa njengeIsithako Esisha Sokudla (NDI), edinga ukuthi abakhiqizi bathumele imibhalo ye-NDIN ngaphandle kwalapho bethola kumnikezeli ngefayela elamukelwe ngaphambilini.

Kokubili i-NMN evamile kanye ne-liposomal idinga ukuthotshelwa kwe-NDIN. Amathimba okuthenga kufanele aqinisekise ukuthi umphakeli wawo omkhethile ugcina imibhalo efanele yokulawula ukuze agweme ukubambezeleka kokuthotshelwa kwemithetho eyehlayo.

 

 

Imakethe ekhula ngokushesha ye-NMN kanye ne-NAD -inenani emhlabeni wonke ngamakhulu ezigidi zamaRandi ngama-CAGR aqagelwa phakathi kuka-5% no-13%-iya ngokuya iqhudelana. Ukuqwashisa kwabathengi ngesayensi yesithako kuyaqhubeka nokukhuphuka, futhiubuchwepheshe bokulethwa kwezidingo buye baba umehluko oyinhloko. Amabhrendi angafakazela ukutholakala kwe-bioavailability okuthuthukisiwe futhi anikeze ukusekelwa kwesayensi kokwakheka kwawo angayala intengo yeprimiyamu edlula kude noma yiziphi izindleko zesithako ezikhuphukayo.

Kulo mongo, isinqumo sokuthola i-liposomal NMN asikona ukukhushulwa kwezindleko-siwutshalo-mali olubeka uphawu lomkhiqizo olusekela amamajini aphezulu, ukwamukelwa okuqinile kwezitolo, kanye nokuncintisana okuncishisiwe okuvela emikhiqizweni yezinga lempahla.

 

 

 

Izindleko Driver	I-NMN evamile	I-Liposomal NMN Powder
Izindleko zezinto ezingavuthiwe/kg	Phansi ($90–220)	Phezulu (ngokujwayelekile 2–3×)
Isidingo somthamo esisebenzayo	Okuphezulu (500–1,000 mg/ngosuku)	Ngaphansi (250-500 mg / ngosuku)
Izindleko ngomthamo ngamunye osebenzayo	Phezulu	Okuphansi noma ukuqhathanisa
Ukulahleka kokuqina (izinyanga eziyi-12-24)	Okumaphakathi (kuzwela kumswakama/ukushisa)	Ngaphansi (ivikelwe i-phospholipid matrix)
Icubungula ukulahlekelwa kwesivuno	Okuncane	Okulingene (encapsulation + drying)
Izidingo zokulawula	I-NDIN iyadingeka	I-NDIN iyadingeka (okufanayo)
Ukuma kwe-Premium	Kuphakathi	Okuqinile (ukwehlukana okusekelwe isayensi)

 

 

Kubaphathi bokuthengwa kwempahla be-B2B nabathuthukisi bomkhiqizo abahlola i-liposomal NMN powder, isinqumo sokuthola asikwazi ukwehliswa sibe ukuqhathaniswa kwentengo elula ngekhilogremu. Lapho kucutshungulwa izidingo zemithamo esebenzayo ephansi, ukuncipha kokuwohloka kokulahlekelwa ngesikhathi sokugcinwa, kanye nemibhalo yokuthobela i-NDI, i-liposomal NMN ivamise ukuletha izindleko eziphansi noma eziqhathanisekayo ngomthamo ngamunye osebenzayo kune-NMN evamile. Ngaphezu kwalokho, ubuchwepheshe buvumela ukuma komkhiqizo we-premium osekelwa isayensi ovikela umkhawulo futhi osekela ukukhula kwesikhathi eside emakethe yokuncintisana ye-NMN. Ukukhetha umphakeli obonisa ngale ngokobuchwepheshe onedatha eqinisekisiwe ye-bioavailability kanye nenqwaba-yemibhalo yokuhlaziya ethile kuyinzuzo yamasu{4}}akuyona nje into yomugqa wokuthenga.

 

Izinyathelo Ezilandelayo Zokwakhiwa Kwakho

Amaklayenti amaningi aqala ngeqoqo lokuhlola (100–500 g) ukuze aqinisekise ukuhlakazeka, ukuzinza, kanye nokusebenza kahle kokuguqulwa ku-matrix yawo ethile ngaphambi kokukalela emkhiqizweni wokuthengisa.

• [Cela amasampula obuchwepheshe] - Hlola amamaki ethu empushana e-liposomal NMN (Amakhulu noma alingana nobumsulwa obungama-98%) ku-matrix yakho.
• [Finyelela kumadokhumenti ezobuchwepheshe] - Buyekeza imibiko yokuhlola ye-HPLC, ukuhlaziywa kwensimbi esindayo, idatha yokuphepha kwe-microbiological, kanye nezifundo zokuzinza zezinyanga ezingu-24.
• [Xoxa ngokucaciswa ngokwezifiso] - Hlola ukugxilisa ngokwezifiso, usayizi wezinhlayiyana, noma izinketho ze-myrosinase co-formulation.
• [Hlela ukubonisana ngokwakhiwa] - Hlangana nethimba lethu le-R&D ukuze ubhekane ne-NMN bioavailability, ukuzinza, noma izinselele ezithile zohlelo lokusebenza.

I-MOQ, isikhathi sokuhola, kanye namanani entengo amaningi atholakala uma ucela. Ukuze uthole ukwesekwa kobuchwepheshe, ukubonisana nokuklama, namakhotheshini ayinqwaba, xhumana nethimba lethu lonjiniyela kuliu@wellgreenxa.com.

 

Izithenjwa

1. Liu, L., et al. (2025).I-Nicotinamide riboside ne-nicotinamide mononucleotide zisiza ukuhlanganiswa kwe-NAD+ ngokujikeleza kwe-enterohepatic.Intuthuko Yesayensi, 11(12), eadr1538. I-DOI: 10.1126/sciadv.adr1538
2. Pencina, KM, et al. (2023).I-MIB-626, ukwakheka komlomo kwe-polymorph eyingqayizivele ye-microcrystalline -ye-nicotinamide mononucleotide, inyusa amazinga ajikelezayo e-NAD+ kubantu abadala abaphakathi nabadala.I-Journals of Gerontology Series A, 78(1), 90–96. I-DOI: 10.1093/gerona/glac049
3. Morifuji, M., et al. (2024).Ukungeniswa -kwe-nicotinamide mononucleotide kukhuphule amazinga e-NAD egazi kanye nemiphumela yokusebenza ethuthukisiwe kubantu abadala.I-GeroScience, 46(5), 4671-4688. I-DOI: 10.1007/s11357-024-01234-9